Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The BID (0.13) and ASK (0.14) tells Today's trading story .... Another DAMN drop ...
hate it !!!!!
February 22, 2018
The Columnist
The Columnist of the Week
Google News
Biotechnology / Healthcare
Alcohol Addiction Therapeutics Market Cost Analysis, Revenue and Gross Margin Analysis with Its Important Types And Application 2018
February 22, 2018 - by amit.p
Alcohol Addiction Therapeutics Market reports cover detailed competitive outlook including the market share and company profiles of the key participants operating in the Global market. The Alcohol Addiction Therapeutics market report provides an in-depth overview of Product Specification, technology, product type and production analysis considering major factors such as Revenue, Cost, Gross and Gross Margin.
Alcohol Addiction Therapeutics Market Manufactures: AstraZeneca Plc, BioCorRx Inc, Bionex Pharmaceuticals LLC, Cerecor Inc, Chronos Therapeutics Ltd, Corcept Therapeutics Inc, Curemark LLC, Eli Lilly and Company, Ethypharm SA, H. Lundbeck A/S.
Get Sample PDF @ https://www.absolutereports.com/enquiry/request-sample/11653289
Alcohol Addiction Therapeutics Market report also include data type such as capacity, production, market share, price, growth rate, consumption, import, export etc. Industry chain, manufacturing process, cost structure, marketing channel are also analyzed in this report.
The Global Alcohol Addiction Therapeutics market is a growing market into Healthcare sector at present years. The Alcohol Addiction Therapeutics has uncovered rapid development in the current and past years and is probably going to proceed with a continuing development in the upcoming years.
Major Highlights of Alcohol Addiction Therapeutics Market report:
• Alcohol Addiction Therapeutics Market Overview
•Industry Chain Analysis
•Manufacturing Analysis of Alcohol Addiction Therapeutics
•Historical, current, and projected size of the market from the standpoint of both value and volume
•Sales Market Forecast
•Market shares and strategies of key players
•New Project Investment Feasibility Analysis
•Regional Market Forecast
Have Any Query? Ask to Expert @ https://www.absolutereports.com/enquiry/pre-order-enquiry/11653289
This report studies Alcohol Addiction Therapeutics in Global market, especially in Europe, North America, China, Japan, Southeast Asia
Alcohol Addiction Therapeutics Market Types
CM-1212
CTDP-002
A-705253
ABT-436
ADX-71441
Others
Alcohol Addiction Therapeutics Market Applications:
Hospital
Clinic
Others
The Alcohol Addiction Therapeutics Market report conveys an essential review of the business including its definition, applications and assembling innovation, Alcohol Addiction Therapeutics Market report introduces the organization profile, item determinations, limit, generation esteem, Contact Information of maker and pieces of the pie for organization.
Browse Detailed TOC, Tables, Figures, Charts and Companies Mentioned in Alcohol Addiction Therapeutics Market Research Report at https://www.absolutereports.com/11653289
Alcohol Addiction Therapeutics Market reports also estimates the sales market analysis of year 2012-2017 with figures like Sales Volume, Sales Price and Sales Revenue Analysis. Report manifest the sales, consumption and production on a regional approach.
The Alcohol Addiction Therapeutics market report covers the present scenario and the growth prospects of the Global Alcohol Addiction Therapeutics market for 2017-2022. To calculate the market size, the report considers the demand for Alcohol Addiction Therapeutics from the key regions.
Key questions answered in the report:
•What will the market size be in 2022 and what will the growth rate be?
•What are the key market trends? What is driving this market?
•What are the challenges to market growth?
•Who are the key vendors in this market space?
•What are the market opportunities and threats faced by the key vendors?
•What are the strengths and weaknesses of the key vendors?
The Alcohol Addiction Therapeutics Market analysis and specialists gives knowledge of Alcohol Addiction Therapeutics industry by patterns, showcase size, offers and income which are the key components recorded in the report.
Purchase Full Report @ http://www.absolutereports.com/purchase/11653289
At last, the report gives the inside and out examination of Alcohol Addiction Therapeutics Market took after by above components, which are useful for organizations or individual for development of their present business or the individuals who are hoping to enter in Alcohol Addiction Therapeutics industry.
SOURCE Columnist of Week https://columnistofweek.com/
Here is my conclusion on the recent PPS drop ...
As I mention before in a previous post, someone is selling 300-400K shares right at or after lunch EVERY DAY for the past 2.5 weeks under BID price ..
For example today :
20k @ 12:06 / 80K @ 12;12 / 15K @12:13 / 190K @12:15 .
So whoever is selling the big bulks of shares will keep selling for the next few days till the PPS drop to an unsatisfactory level for him . then and only then he will quit selling 100s of thousands of shares under BID price .
When that happen the stock will settle and then will gradually start recovering ..
How to expect the stock price to rise while having 100K waiting @ the ASK from the 1st moment of trading ... this is getting VERY annoying !!!
Biotechnology and Substance Abuse Markets Have Positive Projections
9:00 AM ET 2/20/18 | PR Newswire
FinancialBuzz.com News Commentary
NEW YORK, February 20, 2018 /PRNewswire/ --
According to data published by Grand View Research, Inc. the global biotechnology market is projected to reach a value of USD 727.1 billion by 2025. Major technological developments in segments such as regenerative medicine, genetics and diagnostics are important drives for the future of the biotechnology industry. A major segment of the biotech industry is substance abuse treatment. According to Transparency Market Research, U.S. substance abuse treatment market was value at US$4.42 billion in 2015, and is expected to research US$12.43 Billion by 2024. BioCorRx Inc. (OTC: BICX), Egalet Corporation (NASDAQ: EGLT), Regulus Therapeutics Inc. (NASDAQ: RGLS), DURECT Corporation (NASDAQ: DRRX), Titan Pharmaceuticals, Inc. (NASDAQ: TTNP)
Opioids are the most widely prescribed medications or the treatment of chronic pain conditions. Opioids are also a major cause of drug overdoses and substance abuse. The New York Times reported data provided by the CDC, according to which Drug overdoses killed roughly 64,000 people in the United States in 2016. A very strong increase of more than 22 percent from the previous year. Deekshita Allavarapu, Analyst for GBI Research, explains: "The FDA has raised concerns over the high use, and the potential for misuse, of opioids. This could lead to the enforcement of regulatory checks that affect the opioid treatment market and its potential growth."
BioCorRx Inc. (OTCQB: BICX) last week the company announced, "Results of its pre-Investigational New Drug (pre-IND) meeting with the United States Food & Drug Administration (FDA). The FDA has deemed the 505(b) (2) pathway as an acceptable route for approval for BICX102, a sustained release naltrexone implant for the treatment of opioid and alcohol use disorders. The 505(b) (2) pathway is intended to provide an abbreviated route to approval with less study requirements than traditional applications. Based on the FDA's guidance, no additional efficacy studies are being considered. In addition, the Company announced that based on the FDA's responses, it plans to apply for dual indications, both opioid use disorder and alcohol use disorder, within the same application. A nonclinical safety study and a clinical pharmacokinetic (PK) study will be conducted as the Company expected and planned for prior to the pre-IND meeting. Clinical safety and human factor testing will also be performed as suggested by the FDA."
Brady Granier, President, CEO and Director, stated, "We are excited with the responses we have received on our development plan from the FDA. With the FDA agreeing that the 505(b) (2) pathway is acceptable for BICX102, this means that we should be able to help more people, sooner than traditional routes of approval. We expect to have relatively lower costs and a faster path to approval with this abbreviated route. Also, the ability to seek approval on two indications at the same time using the same studies would be an enormous time and cost savings to the Company. The opioid epidemic gets all the headlines for the right reasons, but alcohol use disorder is a continuous, massive problem that we have never neglected. We are particularly grateful for the support we have received from both the National Institute on Drug Abuse (NIDA) and the National Institute on Alcohol Abuse and Alcoholism (NIAAA). Preparation for certain National Institutes of Health (NIH) grant applications are underway now that we have enough information from the FDA to proceed. The submission period for these grants has just started. We also plan to file our IND application soon and hope to have updates available as things progress."
Egalet Corporation (NASDAQ: EGLT), a fully integrated specialty pharmaceutical company, is focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions. On January 23, 2018, the company announced that its partner OraPharma, a division of Valeant Pharmaceuticals International, Inc., has begun promoting SPRIX(R) (ketorolac tromethamine) Nasal Spray to more than 9,000 dentists and oral surgeons across the United States. Under the agreement announced earlier this month, the OraPharma sales team will promote SPRIX Nasal Spray along with their own portfolio of products to their target dentists and oral surgeons. SPRIX Nasal Spray is a nonsteroidal anti-inflammatory drug (NSAID) indicated in adults for short-term (up to five days) management of moderate to moderately severe pain that requires analgesia at the opioid level.
Regulus Therapeutics Inc. (NASDAQ: RGLS) is a clinical stage biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs. On December 19, 2017, the company announced that it has initiated the first-in-human Phase I study of RGLS4326 and completed dosing of the first cohort of healthy volunteers. RGLS4326 is in development for the treatment of autosomal dominant polycystic kidney disease, or ADPKD. RGLS4326 is being studied in a Phase I randomized, double-blind, placebo-controlled, single ascending dose study designed to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of RGLS4326 administered subcutaneously in healthy volunteers.
DURECT Corporation (NASDAQ: DRRX) is a biopharmaceutical company developing therapeutics based on its Epigenetic Regulator Program and proprietary drug delivery platforms. Recently, the company announced that its licensee, Pain Therapeutics, reported that it has resubmitted the New Drug Application (NDA) for REMOXY(R) ER to the U.S. Food and Drug Administration (FDA). REMOXY ER is designed as an abuse-deterrent, extended release, capsule formulation of oxycodone, a prescription drug for severe pain. Pain Therapeutics stated that it expects a six-month review cycle by FDA, and that it expects to be notified by FDA of a Prescription Drug User Fee Act (PDUFA) date within 60 days. REMOXY ER, an investigational drug, is a unique long-acting oral formulation of oxycodone intended to manage pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Based on DURECT's ORADUR(R) technology, which is covered by issued patents and pending patent applications owned by us, REMOXY ER is designed to discourage common methods of tampering associated with prescription opioid analgesic misuse and abuse.
Titan Pharmaceuticals, Inc. (NASDAQ: TTNP), based in South San Francisco, CA, is developing proprietary therapeutics primarily for the treatment of serious medical disorders. The company's lead product is Probuphine(R), a novel and long-acting formulation of buprenorphine for the long-term maintenance treatment of opioid dependence. On January 22, 2018, the company confirmed that it and Braeburn Pharmaceuticals, Inc. are in discussions regarding their partnership for the development and commercialization of Probuphine, the first 6-month maintenance treatment of opioid dependence. "We continue to believe that Probuphine has an important role to play in combatting the national epidemic of opioid addiction," said Executive Chairman Marc Rubin, M.D.
Subscribe Now! Watch us report LIVE https://www.youtube.com/FinancialBuzzMedia
Follow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzz
Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz
Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/
8k out !!!
Current Report Filing (8-k)
Source: Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (date of earliest event reported): February 9, 2018
BioCorRx Inc.
(Exact name of registrant as specified in its charter)
000-54208
(Commission File Number)
Nevada
90-0967447
(State or other jurisdiction of Incorporation)
(I.R.S. Employer Identification No.)
2390 East Orangewood Avenue, Suite 575
Anaheim, California 92806
(Address of principal executive offices)
(714) 462-4880
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 1.01 Entry Into a Material Definitive Agreement.
On February 9, 2018, BioCorRx Inc., a Nevada corporation (the “Company”) entered into a Investment Agreement (the “Investment Agreement”) and a Registration Rights Agreement (the “Registration Rights Agreement”) with Northbridge Financial Inc. (“Northbridge”). Under the terms of the Investment Agreement, Northbridge has agreed to provide the Company with up to ten million dollars ($10,000,000) of funding in the form of purchases of shares of the Company’s common stock. Northbridge will only make these purchases after a registration statement on Form S-1 registering these future shares is declared effective by the Securities and Exchange Commission (the “SEC”).
Following effectiveness of the registration statement, the Company shall have the right to deliver puts to Northbridge and Northbridge will be obligated to purchase registered shares of the Company’s common stock based on the investment amount specified in each put notice. The maximum amount that the Company shall be entitled to put to Northbridge in each put notice shall be equal to twice the average of the daily trading volume for the Company’s common stock during the twelve trading days preceding the put date, so long as such amount does not exceed 4.99% of the outstanding shares of the Company. Pursuant to the Investment Agreement, Northbridge and its affiliates will not be permitted to purchase and the Company many not put registered shares of the Company’s common stock to Northbridge that would result in Northbridge’s beneficial ownership totaling more than 4.99% of the Company’s outstanding common stock. The price of each put registered share shall be equal to 80% percent of the average of the three lowest closing prices traded lowest volume-weighted average price of the Company’s common stock during the twelve trading days preceding the date the applicable put notice is delivered to Northbridge. Puts may be delivered by the Company to Northbridge until the earlier of 36 months after the SEC first declares the registration statement on Form S-1 effective or the date on which Northbridge has purchased an aggregate of $10,000,000 worth of put registered shares.
The foregoing description of the terms of the Investment Agreement and Registration Rights Agreement does not purport to be complete and is qualified in its entirety by the complete text of the documents attached as Exhibit 10.1 and Exhibit 10.2 to this Current Report on Form 8-K.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit 10.1
Investment Agreement
Exhibit 10.2
Registration Rights Agreement
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
BIOCORRX INC.
Date: February 16, 2018
By:
/s/ Lourdes Felix
Lourdes Felix
Chief Financial Officer
3
Big disappointment in the way BICX been trading in the past few days specially after the BEST news ever for that stock ...
There is an intentional manipulation for the stock price !!! someone keeps selling huge blocks under BID price at mid day / every day for 2 weeks now ...!!!
The under bid price selling happens after lunch hours ...
Something weird happening here .. and I am not liking it one bit ..
Normally with the latest news we should be in the mid 0.20s by now ...
Dr. Joseph DeSanto and BioCorRx Recovery Program Participant Appear on the TV Show, The Doctors
Font size: A | A | A
8:00 AM ET 2/15/18 | GlobeNewswire
Dr. Joseph DeSanto and BioCorRx Recovery Program Participant Appear on the TV Show, The Doctors
ANAHEIM, CA, Feb. 15, 2018 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTCQB: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced that Dr. Joseph DeSanto, founder of the DeSanto Clinics and provider of the Company's BioCorRx(R) Recovery Program, appeared on the nationally syndicated daytime talk show, The Doctors. Dr. DeSanto is a Board Certified MD with over 12 years of addiction treatment experience. The episode focuses on the journey of Dr. DeSanto's patient, Anna, who was treated in his clinic using the BioCorRx(R) Recovery Program, which includes the use of a naltrexone implant and the Company's proprietary cognitive behavioral therapy (CBT) program with accompanying peer support. Clips from the episode are available here.
Brady Granier, CEO of BioCorRx, Inc., stated, "We are very proud of Anna. It's takes extreme courage to seek help and then get on a national stage to talk about it. Hopefully her bravery will encourage others to find help. Although it wasn't mentioned by name during the show, Anna participated in a protocol that we call B2NTX, which can be found on our website at www.BeatAddiction.com. That protocol includes the use of our BioCorRx(R) Recovery Program which Dr. DeSanto uses frequently in his practice."
You can use that link as brochure / presentation for BICX ..
https://d1io3yog0oux5.cloudfront.net/_9fd498f943c4586399d51e712b8496ac/biocorrx/db/278/547/pdf/BICX+Investor+Presentation+June+Final+NR.pdf
One BUY trade for 317k a minute before close !!!!!
Great day with Great news & an awesome close !!!
What kind of trading that is ?
Really !!!!!!!!!!!!!!!!!!
That type of news and PPS drops ????
Today's PR is a CLEAR indication where Biocorrx will be in the near future .. Today's PR moved BICX to a completely different level of investors interest ... Today's PR is a payoff for all longs ....
from today's PR
" Preparation for certain National Institutes of Health (NIH) grant applications are underway now that we have enough information from the FDA to proceed. The submission period for these grants has just started. We also plan to file our IND application soon and hope to have updates available as things progress."
BioCorRx Announces Results of Pre-IND meeting with FDA for Sustained Release Naltrexone Implant, BICX102
Font size: A | A | A
9:22 AM ET 2/12/18 | GlobeNewswire
BioCorRx Announces Results of Pre-IND meeting with FDA for Sustained Release Naltrexone Implant, BICX102
505(b)(2) application plan acceptable per FDA
Application will seek dual indications for opioid and alcohol use disorders
ANAHEIM, CA, Feb. 12, 2018 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTCQB: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced results of its pre-Investigational New Drug (pre-IND) meeting with the United States Food & Drug Administration (FDA). The FDA has deemed the 505(b)(2) pathway as an acceptable route for approval for BICX102, a sustained release naltrexone implant for the treatment of opioid and alcohol use disorders. The 505(b)(2) pathway is intended to provide an abbreviated route to approval with less study requirements than traditional applications. Based on the FDA's guidance, no additional efficacy studies are being considered. In addition, the Company announced that based on the FDA's responses, it plans to apply for dual indications, both opioid use disorder and alcohol use disorder, within the same application. A nonclinical safety study and a clinical pharmacokinetic (PK) study will be conducted as the Company expected and planned for prior to the pre-IND meeting. Clinical safety and human factor testing will also be performed as suggested by the FDA.
Brady Granier, President, CEO and Director, stated, "We are excited with the responses we have received on our development plan from the FDA. With the FDA agreeing that the 505(b)(2) pathway is acceptable for BICX102, this means that we should be able to help more people, sooner than traditional routes of approval. We expect to have relatively lower costs and a faster path to approval with this abbreviated route. Also, the ability to seek approval on two indications at the same time using the same studies would be an enormous time and cost savings to the Company. The opioid epidemic gets all the headlines for the right reasons, but alcohol use disorder is a continuous, massive problem that we have never neglected. We are particularly grateful for the support we have received from both the National Institute on Drug Abuse (NIDA) and the National Institute on Alcohol Abuse and Alcoholism (NIAAA). Preparation for certain National Institutes of Health (NIH) grant applications are underway now that we have enough information from the FDA to proceed. The submission period for these grants has just started. We also plan to file our IND application soon and hope to have updates available as things progress."
About BioCorRx
BioCorRx Inc. (OTCQB: BICX) is an addiction treatment company offering a unique approach to the treatment of substance abuse addiction. The BioCorRx(R) Recovery Program, a non-addictive, medication-assisted treatment (MAT) program, consists of two main components. The first component of the program consists of the use of sustained release naltrexone, usually in implantable form and under the direction and care of an independent licensed physician. Implant forms of naltrexone deliver the non-addictive medicine which is an opioid antagonist that can significantly reduce physical cravings for alcohol and opioids, as well as some of their effects. The second component of the program developed by BioCorRx Inc. is a proprietary cognitive behavioral therapy (CBT) program specifically tailored for the treatment of alcohol and opioid use disorders for those receiving sustain release naltrexone treatment. The behavioral portion of the program also includes overlapping peer recovery support and tracking. The Company also has an R&D subsidiary, BioCorRx Pharmaceuticals, which is currently developing injectable and implantable naltrexone products for potential future regulatory approval. For more information on BICX, visit www.BioCorRx.com.
Safe Harbor Statement
The information in this release includes forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "become," "plan," "will," and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.
BioCorRx Inc.
investors@BioCorRx.com
714-462-4880
Investor Relations:
Crescendo Communications, LLC
(212) 671-1020 x304
nrudman@crescendo-ir.com
> Dow Jones Newswires
February 12, 2018 09:22 ET (14:22 GMT)
Even though the trading volume today is not that HUGE so far but it's all BUYS ;)
VERY POSITIVE PR !!!!
BioCorRx Extends Service Agreement with Dr. Balbir S. Brar as VP of Drug Development Following Pre-IND Meeting with the U.S. FDA
7:30 AM ET 2/8/18 | GlobeNewswire
BioCorRx Extends Service Agreement with Dr. Balbir S. Brar as VP of Drug Development Following Pre-IND Meeting with the U.S. FDA
ANAHEIM, CA, Feb. 08, 2018 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTC: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced that following the pre-Investigational New Drug (pre-IND) meeting with the U.S. Food and Drug Administration (FDA), and based on the FDA's responses to the Company's development plan for BICX102, it has extended Dr. Balbir S. Brar's agreement as VP of Drug Development for the BioCorRx Pharmaceuticals subsidiary for an additional one year period.
Brady Granier, President, CEO and Director, stated, "Dr. Brar's guidance and expertise has been extremely valuable as we move forward with our plans for BICX102, a sustained release naltrexone implant for the treatment of opioid and alcohol use disorders. We feel that his contributions to the briefing package which was submitted to the FDA played a huge role in what we believe was a very productive and successful meeting. We are very appreciative that he has agreed to continue with us on the next steps for BICX102."
Dr. Brar, VP of Drug Development, commented, "The FDA meeting was a very positive next step for the company as we seek to commercialize our sustained release naltrexone implant. This product addresses a multi-billion dollar, underserved market with few viable options for patients. I look forward to helping further advance and accelerate the regulatory approval process for this life saving product."
Dr. Brar has over 25 years of experience in drug and device development, including worldwide regulatory submissions for over 50 INDs, 510(k)s and 505(b)(2)s, as well as approval of 8 NDAs for drugs currently on the market. Dr. Brar's experience includes working with major pharmaceutical companies such as Lederle/Wyeth, where he was instrumental in the development of Azmacort for asthma, as well as topical Aristocort. At GlaxoSmithKline, as Director of Drug Safety, Dr. Brar participated in the development of Tazarotene. At Allergan, as VP of Drug Safety, he made major contributions towards the development, regulatory submission, and approval of Botox, Alphagan, Lumigan, Restasis, Ofloxacin, Azelex, and Avage.
For the past 10 years Dr. Brar has played a leadership role for several early stage biotechnology companies in the fields of nephropathy, oncology, ophthalmology, dermatology, pain, and cardiology. During this time, Dr. Brar served on the Board of Directors, and acted as President, EVP R&D, and Chief Technology Officer. Dr. Brar has a Ph.D. in Toxicology/Pathology from Rutgers University and D.V.M. from a university in India with finance training from Harvard Business School.
Huge trade just went through !!!
Averaging down / buying more shares is a must during the quiet period . When news comes out and it will , buying more shares will be much more expensive ... Go BICX
Big buys happening !
Were able to reach out for "Granier" through FB . asked him about the FDA meetings updates . replied back that he is waiting for the federal government timeline to release the meeting minutes. added the he is PLEASED with the meeting and they are moving ahead with the BICX102 development ..,....... Very positive IMO
Another greeeeeeen close lol
Have a good feeling about this week !!
Global Substance Abuse and Addiction Treatment Market Projected to Grow
9:00 AM ET 2/5/18 | Dow Jones
FinancialBuzz.com News Commentary
NEW YORK, February 5, 2018 /PRNewswire/ --
According to a report by BCC research the global substance abuse and addiction treatment market has the potential to reach $4.4 billion annually by 2021. The main reason for the global rise in substance abuse, substance dependence, and addiction treatment is the increasing use of psychoactive substances. The report also indicates that the substance abuse and addiction treatment market is categorized into three types based on condition: nicotine, alcohol, and drugs. Drug dependence is the largest segment. In 2016, the drug abuse segment recorded the highest revenue, at $2.3 billion. BioCorRx Inc. (OTC: BICX), Elite Pharmaceuticals, Inc. (OTC: ELTP), Titan Pharmaceuticals, Inc. (NASDAQ: TTNP), DURECT Corporation (NASDAQ: DRRX), ImmunoCellular Therapeutics, Ltd. (NYSE: IMUC),
A major portion of the substance abuse market is the opioid abuse segment, which is projected to be valued at $2.5 billion by 2021. Addiction to opioids is on the rise and is leading to serious health problems. BCC Research analyst and report author, Yojana Jeevane, explained, "Drug abuse is a serious health problem affecting peoples' lives and often ruining families... Therefore, it is of prime importance to monitor and control drug abuse, through drug testing that can measure the use of drugs and helps in the evaluation and proper treatment of addiction."
BioCorRx Inc. (OTCQB: BICX) on January 26th the company announced, "that it held a pre-Investigational New Drug (pre-IND) meeting with the U.S. Food and Drug Administration (FDA) on January 24, 2018 regarding the Company's naltrexone implant, BICX102. BICX102 is the Company's sustained release naltrexone implant for the treatment of opioid and alcohol use disorders.
The National Institute on Drug Abuse (NIDA) joined the meeting as observers, along with Brady Granier, CEO and Director of BioCorRx, and the Company's regulatory experts and consultants. In the meeting, BioCorRx discussed the responses that were received prior to the meeting from the FDA in regard to the pre-IND package, which had been submitted last month. The package included information on BICX102, as well as the proposed development plan for commercialization. As a result of the meeting, the Company plans to move forward with the product as anticipated.
Brady Granier, President, CEO and Director of BioCorRx, stated, "We are pleased with the FDA's responses to our development plan and appreciative of their time in the meeting. We look forward to providing a more thorough update as soon as we receive and review the meeting minutes from the FDA as to confirm all items verbally discussed. In the meantime, we will continue moving forward with our BICX102 plans."
Elite Pharmaceuticals, Inc. (OTCQB: ELTP) is a specialty pharmaceutical company which is developing a pipeline of proprietary pharmacological abuse-deterrent opioid products as well as niche generic products. Recently, the company reported positive topline results from a pilot study conducted for SequestOx(TM), Elite's immediate release Oxycodone Hydrochloride product that incorporates its proprietary abuse-deterrent technology. SequestOx is Elite's investigational abuse-deterrent immediate-release oxycodone product with sequestered naltrexone for the management of moderate to severe acute pain where the use of an opioid analgesic is appropriate. The study was a Phase 1 pilot, randomized, single-dose, single period, pharmacokinetic study in healthy male and female volunteers in the fed state. The test products included two formulation modifications of SequestOx, a unique abuse-deterrent formulation without sequestered naltrexone, and a reference product. The following table summarizes the Tmax results for the pilot study.
Titan Pharmaceuticals, Inc. (NASDAQ: TTNP), based in South San Francisco, CA, is developing proprietary therapeutics primarily for the treatment of serious medical disorders. The company's lead product is Probuphine(R), a novel and long-acting formulation of buprenorphine for the long-term maintenance treatment of opioid dependence. On January 22, 2018, the company confirmed that it and Braeburn Pharmaceuticals, Inc. are in discussions regarding their partnership for the development and commercialization of Probuphine, the first 6-month maintenance treatment of opioid dependence. "We continue to believe that Probuphine has an important role to play in combatting the national epidemic of opioid addiction," said Executive Chairman Marc Rubin, M.D. "To that end, our goal is to make certain that Probuphine is positioned for commercial success, and we will explore all available opportunities to achieve that. We look forward to working with Canaccord Genuity to assist us in this endeavor."
DURECT Corporation (NASDAQ: DRRX) is a biopharmaceutical company actively developing new therapeutics based on its Epigenetic Regulator Program and proprietary drug delivery platforms. On December 13, 2017, the company announced that Indivior PLC has reported that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for RBP-7000. RBP-7000 is an investigational, once-monthly injectable risperidone for the treatment of schizophrenia. Indivior PLC further reported that the FDA has set a PDUFA (Prescription Drug User Fee Act) target action date of July 28, 2018. Indivior is a global specialty pharmaceutical company with a 20-year legacy of leadership in patient advocacy and health policy while providing education on evidence-based treatment models that have revolutionized modern addiction treatment. Indivior is dedicated to transforming addiction from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of opioid dependence treatments, Indivior has a strong pipeline of product candidates designed to both expand on its heritage in this category and address other chronic conditions and co-occurring disorders of addiction, including alcohol use disorder and schizophrenia.
ImmunoCellular Therapeutics, Ltd. (NYSE: IMUC) is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. On December 13, 2017, the company announced that it has achieved a key milestone in its research-stage Stem-to-T-Cell immuno-oncology program. The milestone represents an important step toward stimulating the patient's immune system to produce an unlimited supply of killer T cells that specifically target and destroy tumor cells with minimal side effects. This approach could be effective in treating many types of cancers. The research team at ImmunoCellular successfully packaged a T cell receptor (TCR) DNA sequence into a lentiviral vector, which was then used to transfect human hematopoietic stem cells. The Company has been able to verify successful transfer of genetic material into the stem cells, and plans to continue to work toward optimizing the transfection process. The Company believes that this completed phase of the Stem-to-T-Cell development is an important component of the proof-of-concept work for this technology, and represents a critical step in advancing toward preclinical testing.
Subscribe Now! Watch us report from LIVE https://www.youtube.com/FinancialBuzzMedia
Follow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzz
Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz
Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/
About FinancialBuzz.com
FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.
Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the 'Site') is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting high quality and sophisticated content on FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. FinancialBuzz.com only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. FinancialBuzz.com has not been compensated by any companies mentioned. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. FinancialBuzz.com will always disclose any compensation in securities or cash payments for financial news dissemination and PR
(MORE TO FOLLOW) Dow Jones Newswires
February 05, 2018 09:00 ET (14:00 GMT)
Global Substance Abuse and Addiction Treatment -2-
advertising. FinancialBuzz.com does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use. Please visit: http://www.financialbuzz.com .
For further information:
info@financialbuzz.com
+1-877-601-1879
Url: http://www.FinancialBuzz.com
Well !! You said enough Kizer lol
Green close lol
Big BID support happening right now !!!
Was it ??
@ minute 102 to be exact.
THE RECOVERY SHOW RADIO ABOUT BIOCORRX !!!
http://recoveryshow.org/biocorrx-mat-and-the-naltrexone-implant/
Moving your ASK higher will make us go up quick ... !!
Agree !! VERY STRONG feeling we will
The Quick rebound is an indication that there are positive news hitting the Wire any minutes .. Usually someone knows something when the stock reacts that way !
I guess hit the ASK if want in !!!!
BID squeezing ASK
Why would someone sell a stock he owns while it has a product that is Potential FDA approval ? Why ?
Woooooow scary ride for sure
Agree !! But seriously I don't see 1 good logic reason to SELL now .. just waiting for another week or two might pay off big time ...